Supplemental Figure 4 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy

Supplemental Figure 4: Assessing differences between B16KVP and B16F10 in the absence of ACT. (A) Volcano plot depicting differentially expressed genes in the tumors of mice with neoantigen (B16KVP) versus wild-type (B16F10) tumors in the absence of ACT (n=5 mice/group). Red lines depict a p-value of 0.05 and log2 fold change of ± 0.05. (B) Top significantly enriched genes in the B16KVP NT mice compared to the B16F10 NT. (C) Pathway analysis of significantly upregulated genes enriched in the B16KVP-tumored mice. GO enrichment analysis, biological pathways used. (D) For genes shared between the B16KVP + ACT versus B16F10 + ACT comparison and B16KVP NT versus B16F10 NT comparisons, the relative expression was evaluated (E) Individual tumor curves of mice bearing B16F10 or B16KVP tumors and administered either isotype or anti-PD-1 antibody on days 7, 10, 14, 17, 21, and 24 (n=5-10 mice/group).